Windlas Biotech Limited

BSE: 543329 NSE: WINDLAS
Windlas Biotech Limited - pharma in Dehradun, Uttarakhand, India. FY 2026 financials & compliance.
CIN L74899UR2001PLC033407 Incorporated 19 February 2001 ROC Uttarakhand HQ Dehradun, Uttarakhand, India
Active Listed - NSE: WINDLAS · BSE: 543329 Public Limited Company pharma
Data last updated
Market Cap
₹2,234 Cr
WINDLAS · NSE
Share Price
₹1,075.80
-1.42% today
Revenue
₹904 Cr
FY 2025-26 · +20.1% YoY
EBITDA
₹105 Cr
Margin 11.6%
Net Profit
₹66.46 Cr
FY 2025-26 · +9.0% YoY
P/E (TTM)
33.9x
P/B 3.9x
ROE
12.2%
ROCE 15.8%
Debt / Equity
0.06
Interest cover 6.5x

About Windlas Biotech Limited

Data last updated:

Windlas Biotech Limited is a public limited company based in Dehradun, Uttarakhand, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 19 February 2001, the company has been in operation for over 25 years.

Registered with ROC Uttarakhand under CIN L74899UR2001PLC033407. Listed on BSE: 543329 and NSE: WINDLAS.

Capital: an authorised share capital of ₹77.5 Cr and a paid-up capital of ₹10.55 Cr. Formerly known as Windlas Biotech Private Limited. It is led by directors including Pawan Kumar Sharma and Prachi Jain Windlass.

Last AGM: 28 July 2025. Financial statements filed for year ended 31 March 2025. Office: 40/1 Mohabewala Industrial Area, Dehradun, Uttarakhand, India – 248110.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹904.09 Cr, a growth of 18.98% compared to the previous year. The net worth stands at ₹580.84 Cr (up 14.84% YoY). Total assets are valued at ₹619.51 Cr (up 14.44% YoY).

The company has a workforce of approximately 1,153 employees as per the latest available data.

The company is associated with 1 brand - Windlas. As per MCA filings, the company has open charges of ₹73.3 Cr and satisfied charges of ₹183.4 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website windlas.com.

Company Details of Windlas Biotech Limited
CIN L74899UR2001PLC033407
Registration Number 033407
Incorporation Date 19 February 2001
ROC Uttarakhand
Listing Status Listed (BSE: 543329, NSE: WINDLAS)
Company Status Active
Date of Last AGM 28 July 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Hitesh Windlass Managing Director Manoj Kumar Windlass Managing Director Pawan Kumar Sharma Whole-Time Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    windlas.com
  • Social Media
  • Registered Address
    40/1 Mohabewala Industrial Area, Dehradun, Uttarakhand, India – 248110
  • Industry
    Pharma, Drug Formulation & Development
Company report
Windlas Biotech Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Windlas Biotech Limited report

Financials, compliance, directors, charges, ownership and filings for Windlas Biotech Limited in one report.

10-year financials Directors & ownership Charges & compliance

CIN History of Windlas Biotech

Windlas Biotech has 3 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L74899UR2001PLC033407, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L74899UR2001PLC033407Current
U74899UR2001PLC033407Previous
U74899DL2001PLC109721Previous
U74899UR2001PTC033407Previous

Associated Brands with Windlas Biotech

Windlas Biotech operates one associated brand: Windlas. Each brand links to its own profile.

BrandDescriptionWebsite
Windlas
Biopharma regulatory affairs, quality control, and strategy services are provided.windlas.com

Competitors & Alternatives of Windlas Biotech

Brands and companies operating in the same space as Windlas Biotech Limited include Jubilant Life Sciences, Akums, Nectar Lifesciences and 4 more.

CompetitorDescriptionLocationFounded
Jubilant Life Sciences Jubilant Life Sciences Company offering a suite of R&D and manufacturing services for small molecules and genericsNoida, India, India1978
Akums Akums CDMO focusing on spectrum of dosage forms and therapeutic segmentsDelhi, India, India2004
Nectar Lifesciences Nectar Lifesciences Cephalosporin APIs and generic formulations are manufactured.Chandigarh, India, India1995
Unither Unither Contract development and manufacturing organization for proprietary and generic drugsParis, France, France1993
Recipharm Recipharm Pharmaceutical development and manufacturing services are offered contractually.Jordbro, Sweden, Sweden1995
CoreRx CoreRx CDMO with a focus on early phase drug product developmentClearwater, United States, United States2006
MedPharm MedPharm Topical and inhaled drug delivery formulations are developed and manufactured.Guildford, United Kingdom, United Kingdom1998

Business Activity of Windlas Biotech

The main business activity of Windlas Biotech is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group CodeDescription of Main ActivityBusiness Activity CodeDescription of Business ActivityTurnover Percentage
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical productsLocked
Premium access

Business activity turnover details for Windlas Biotech Limited

Turnover share and past changes in activity are in the company report.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Windlas Biotech

Windlas Biotech Limited is audited by SS KOTHARI METHA & COMPANY LLP for the financial year 2025.

NameStatusAppointment DateCessation Date
SS KOTHARI METHA & COMPANY LLPLockedLockedLocked
Premium access

Complete auditor history for Windlas Biotech Limited

Appointment and cessation dates and past auditor changes are in the company report.

  • Appointment status
  • Appointment dates
  • Cessation dates
  • Auditor changes

Verified entity values are shown only after access is granted.

Board of Directors of Windlas Biotech Limited

Windlas Biotech has 8 current directors and 12 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Pawan Kumar SharmaWhole-Time Director11 Jun 20197 Years 3 MonthsCurrent
Prachi Jain Windlass
Also directs: Michael & Susan Dell Foundation India LLP
Director03 May 20215 Years 5 MonthsCurrent
Vivek DhariwalDirector06 May 20215 Years 4 MonthsCurrent
Gaurav Gulati
Also directs: Aroa Innovation Partners LLP, Redsprig Innovation Partners LLP, Dagrowave Agscience Private Limited and 5 more
Director06 May 20215 Years 4 MonthsCurrent
Hitesh WindlassManaging Director21 Jan 200818 Years 8 MonthsCurrent
Manoj Kumar Windlass
Also directs: Windlas Exports Private Limited
Managing Director01 Apr 200620 Years 6 MonthsCurrent
Showing 6 of 8 current directors. View all directors

Financials of Windlas Biotech Limited FY 2025-26 filings available

Windlas Biotech Limited reported revenue of ₹904.09 Cr (up 18.98% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹904 Cr
+19.0% YoY
EBITDA
₹105 Cr
+11.3% YoY
Profit After Tax
₹66.46 Cr
+9.0% YoY
Net Worth
₹581 Cr
+14.8% YoY
Total Assets
₹620 Cr
+14.4% YoY
Total Debt
₹35.25 Cr
+8.1% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue904760631513466428329
Revenue growth+20.1%+20.4%+22.1%+9.5%+3.3%+35.8%+9.4%
EBITDA10594.1078.1760.2352.4127.2634.00
EBITDA margin+11.6%+12.4%+12.4%+11.7%+11.3%+6.4%+10.3%
Profit before tax86.9879.7577.0957.0545.5521.7424.67
Net profit66.4660.9858.1841.9938.0731.3116.23
Net profit margin+7.4%+8.0%+9.2%+8.2%+8.2%+7.3%+4.9%
EPS (₹)31.4929.1027.9820.3717.4824.7025.29
Balance sheet
Total assets620541456410403233240
Net worth581506450402395199210
Total debt35.2532.603.644.996.6432.3528.93
Cash & bank1.8115.9330.9525.4511431.1118.38
Net working capital70.6482.6687.7312822910947.15
Cash flow
Cash from operations10568.1910960.979.1311.4625.01
Cash from investing(91.79)(74.06)(92.07)(14.11)(155)(20.20)(14.34)
Cash from financing(13.03)1.01(15.29)(43.74)1300.78(5.44)
ParticularsMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
Revenue238233222210203195187175
Revenue growth (YoY)+17.7%+19.5%+18.9%+20.0%+18.3%+20.2%+22.5%+21.0%
Other income4.354.573.655.244.944.114.844.13
EBITDA25.2924.3728.5626.5225.5524.6323.0520.88
EBITDA margin+10.6%+10.5%+12.8%+12.6%+12.6%+12.6%+12.3%+11.9%
Depreciation8.007.707.607.458.346.946.506.21
Interest1.481.281.021.061.331.461.100.49
Profit before tax20.1619.9623.5923.2520.8220.3420.2918.31
Tax4.184.975.795.594.554.764.634.83
Net profit15.9814.9917.8017.6616.2715.5815.6613.48
EPS (₹)7.497.058.408.347.697.387.436.47
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue904760631513466428329
Revenue growth+20.1%+20.4%+22.1%+9.6%+1.9%+40.6%+18.2%
EBITDA10594.1178.1060.2552.8822.3440.67
EBITDA margin+11.6%+12.4%+12.4%+11.7%+11.4%+5.2%+12.4%
Profit before tax86.9479.3977.0357.0746.0211.1730.57
Net profit66.4460.6458.1542.0138.5419.4922.46
Net profit margin+7.4%+8.0%+9.2%+8.2%+8.3%+4.6%+6.8%
EPS (₹)31.4828.9427.9620.3817.697.8135.03
Balance sheet
Total assets620541456410404233245
Net worth581506450403395199216
Total debt35.2532.603.644.996.6432.3527.43
Cash & bank1.8115.9230.9025.4511430.9618.38
Net working capital70.6482.9788.0812822910947.67
Cash flow
Cash from operations10568.2310960.989.0011.4520.87
Cash from investing(91.79)(74.06)(92.07)(14.11)(154)(20.19)(9.16)
Cash from financing(13.03)1.01(15.29)(43.74)1300.78(6.48)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue248238233222210203195187
Revenue growth (YoY)+18.1%+17.7%+19.5%+18.9%+20.0%+18.3%+20.2%+22.5%
Other income5.114.404.523.655.244.943.734.84
Total expenses221213209194184177170164
EBITDA26.6825.2424.3728.5626.5225.5524.6423.05
EBITDA margin+10.8%+10.6%+10.5%+12.8%+12.6%+12.6%+12.6%+12.3%
Depreciation7.218.007.707.607.458.346.946.50
Interest1.651.481.281.021.061.331.461.10
Profit before tax22.9320.1619.9123.5923.2520.8219.9720.29
Tax5.284.154.975.795.594.554.744.63

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 02 Oct 2026
ParticularsMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
Revenue238233222210203195187175
Revenue growth (YoY)+17.7%+19.5%+18.9%+20.0%+18.3%+20.2%+22.5%+21.0%
Other income4.354.573.655.244.944.114.844.13
EBITDA25.2924.3728.5626.5225.5524.6323.0520.88
EBITDA margin+10.6%+10.5%+12.8%+12.6%+12.6%+12.6%+12.3%+11.9%
Depreciation8.007.707.607.458.346.946.506.21
Interest1.481.281.021.061.331.461.100.49
Profit before tax20.1619.9623.5923.2520.8220.3420.2918.31
Tax4.184.975.795.594.554.764.634.83
Net profit15.9814.9917.8017.6616.2715.5815.6613.48
EPS (₹)7.497.058.408.347.697.387.436.47
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue904760631513466428329
Revenue growth+20.1%+20.4%+22.1%+9.5%+3.3%+35.8%+9.4%
Other income17.8018.0213.479.976.718.742.49
Total expenses799666553453414400295
Employee cost15212387.4670.3263.4158.3243.57
EBITDA10594.1078.1760.2352.4127.2634.00
EBITDA margin+11.6%+12.4%+12.4%+11.7%+11.3%+6.4%+10.3%
Depreciation30.7427.9913.4412.3612.1512.979.29
Interest4.834.381.110.791.421.292.53
Profit before tax86.9879.7577.0957.0545.5521.7424.67
Tax20.5218.7618.9114.417.476.178.45
Net profit66.4660.9858.1841.9938.0731.3116.23
Net profit margin+7.4%+8.0%+9.2%+8.2%+8.2%+7.3%+4.9%
EPS (₹)31.4929.1027.9820.3717.4824.7025.29
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital10.5510.4810.4010.4610.906.416.41
Reserves & surplus570495440392384193203
Shareholders' funds (net worth)581506450402395199210
Minority interest0.000.000.000.000.000.000.00
Secured loans29.8827.120.110.445.7630.2427.43
Unsecured loans5.375.483.534.550.882.111.50
Total debt35.2532.603.644.996.6432.3528.93
Total liabilities620541456410403233240
Assets
Gross block36734727519416415779.35
Net block21322317910991.1895.9470.26
Capital work in progress59.595.325.7114.788.010.040.00
Investments26822317310764.8223.14116
Inventories61.8281.3862.1974.7458.7141.4649.32
Sundry debtors22716713611711179.4163.94
Cash & bank balances1.8115.9330.9525.4511431.1118.38
Loans & advances67.4437.5928.4429.9733.5219.1914.11
Total current assets358302258247317171146
Total current liabilities28821917011987.7962.4198.60
Net working capital70.6482.6687.7312822910947.15
Total assets620541456410403233240
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.425.293.690.5715.9323.9012.86
Net cash from operating activities10568.1910960.979.1311.4625.01
Net cash from investing activities(91.79)(74.06)(92.07)(14.11)(155)(20.20)(14.34)
Net cash from financing activities(13.03)1.01(15.29)(43.74)1300.78(5.44)
Net change in cash0.11(4.86)1.603.12(15.36)(7.97)5.22
Closing cash1.8115.9330.9525.4511431.1118.38
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+19.0%+20.4%+23.0%+10.1%+9.0%+30.0%+7.0%
EBITDA growth+11.3%+20.4%+29.8%+14.9%+92.3%-19.8%-9.9%
PBT growth+9.1%+3.5%+35.1%+25.3%+109.5%-11.9%-67.6%
Net income growth+9.0%+4.8%+38.6%+10.3%+21.6%+92.9%-27.1%
Revenue CAGR (3Y)+20.8%+17.7%+13.9%+16.0%+14.9%+6.7%-
EBITDA CAGR (3Y)+20.3%+21.5%+42.1%+21.0%+11.6%-11.5%-
Profitability & leverage
Net income margin+7.4%+8.0%+9.2%+8.3%+8.2%+3.6%+4.9%
Return on capital employed+15.8%+16.9%+18.1%+14.2%+14.8%+18.9%+11.7%
Return on net worth+12.2%+12.8%+13.7%+10.7%+12.8%+15.2%+8.0%
Debt / equity0.060.040.010.010.070.150.15
Long-term debt / equity0.000.000.010.000.000.010.02
Interest cover6.536.631.711.653.539.0310.24
Efficiency & per share
Fixed asset turnover2.542.452.692.872.903.624.01
Inventory turnover12.6310.599.227.699.309.429.62
Debtors turnover4.595.014.994.514.905.975.23
EPS (₹)31.4929.1027.9820.3717.4824.7025.29
Dividend per share (₹)6.305.805.504.003.500.000.00
Book value per share (₹)275.20241.30216.34192.24181.14310.59327.03
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue248238233222210203195187
Revenue growth (YoY)+18.1%+17.7%+19.5%+18.9%+20.0%+18.3%+20.2%+22.5%
Other income5.114.404.523.655.244.943.734.84
Total expenses221213209194184177170164
EBITDA26.6825.2424.3728.5626.5225.5524.6423.05
EBITDA margin+10.8%+10.6%+10.5%+12.8%+12.6%+12.6%+12.6%+12.3%
Depreciation7.218.007.707.607.458.346.946.50
Interest1.651.481.281.021.061.331.461.10
Profit before tax22.9320.1619.9123.5923.2520.8219.9720.29
Tax5.284.154.975.795.594.554.744.63
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue904760631513466428329
Revenue growth+20.1%+20.4%+22.1%+9.6%+1.9%+40.6%+18.2%
Other income17.8017.6513.479.976.713.090.96
Total expenses799666553453413405288
Employee cost15212387.4670.3263.4158.3243.88
EBITDA10594.1178.1060.2552.8822.3440.67
EBITDA margin+11.6%+12.4%+12.4%+11.7%+11.4%+5.2%+12.4%
Depreciation30.7427.9913.4412.3612.1512.978.69
Interest4.834.381.100.791.421.292.37
Profit before tax86.9479.3977.0357.0746.0211.1730.57
Tax20.5018.7418.8814.417.476.178.11
Net profit66.4460.6458.1542.0138.5419.4922.46
Net profit margin+7.4%+8.0%+9.2%+8.2%+8.3%+4.6%+6.8%
EPS (₹)31.4828.9427.9620.3817.697.8135.03
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital10.5510.4810.4010.4610.906.416.41
Reserves & surplus570495440392384193210
Shareholders' funds (net worth)581506450403395199216
Secured loans29.8827.120.110.446.1230.2422.16
Unsecured loans5.375.483.534.550.522.115.27
Total debt35.2532.603.644.996.6432.3527.43
Total liabilities620541456410404233245
Assets
Gross block367346274193164157141
Net block21322317910991.1895.9468.43
Capital work in progress59.595.325.7114.788.010.040.00
Investments26822317310764.8623.18121
Inventories61.8281.3862.1974.7458.7141.4649.32
Sundry debtors22716713611711179.4164.56
Cash & bank balances1.8115.9230.9025.4511430.9618.38
Loans & advances67.4437.8928.4429.9733.5219.1814.11
Total current assets358302258247317171146
Total current liabilities28821917011987.4662.4298.70
Net working capital70.6482.9788.0812822910947.67
Total assets620541456410404233245
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.425.243.690.5515.7823.7412.86
Net cash from operating activities10568.2310960.989.0011.4520.87
Net cash from investing activities(91.79)(74.06)(92.07)(14.11)(154)(20.19)(9.16)
Net cash from financing activities(13.03)1.01(15.29)(43.74)1300.78(6.48)
Net change in cash0.11(4.82)1.563.13(15.22)(7.97)5.22
Closing cash1.8115.9230.9025.4511430.9618.38
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+19.0%+20.4%+23.0%+10.1%+9.0%+30.0%+14.1%
EBITDA growth+11.3%+20.5%+29.6%+13.9%+136.7%-45.1%-8.5%
PBT growth+9.5%+3.1%+35.0%+24.0%+312.0%-63.5%-12.3%
Net income growth+9.6%+4.3%+38.4%+9.0%+97.7%-13.2%+1.6%
Revenue CAGR (3Y)+20.8%+17.7%+13.9%+16.0%+17.4%+10.1%+1.4%
EBITDA CAGR (3Y)+20.2%+21.2%+51.8%+14.0%+6.0%-16.5%+17.9%
Profitability & leverage
Net income margin+7.4%+8.0%+9.2%+8.3%+8.3%+1.2%+6.8%
Return on capital employed+15.8%+16.8%+18.0%+14.2%+14.9%+18.8%+14.0%
Return on net worth+12.2%+12.7%+13.6%+10.7%+13.0%+9.4%+10.9%
Debt / equity0.060.040.010.010.070.140.14
Long-term debt / equity0.000.000.010.000.000.010.02
Interest cover6.536.621.701.653.4913.777.41
Efficiency & per share
Fixed asset turnover2.542.452.702.872.902.872.47
Inventory turnover12.6310.599.227.699.309.429.62
Debtors turnover4.595.014.994.514.905.945.19
EPS (₹)31.4828.9427.9620.3817.697.8135.03
Dividend per share (₹)6.305.805.504.003.500.000.00
Book value per share (₹)275.20241.31216.51192.42181.30310.39337.66
Want more history and ratios?
You're viewing the latest exchange-filed financials for Windlas Biotech Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Windlas Biotech Limited

Shareholding for the quarter ended Sep 2026: promoters hold 63.30%, foreign institutional investors hold 2.00%, domestic institutional investors hold 9.90% and retail and other public shareholders hold 24.80%.

Promoters: 63.30%DII (Domestic Institutional): 9.90%FII (Foreign Institutional): 2.00%Retail & Others: 24.80%
Sep 2026
QUARTER
63.30% Promoters
9.90% DII (Domestic Institutional)
2.00% FII (Foreign Institutional)
24.80% Retail & Others
Promoter holding - history
Now 63.30% · Sep 2026High 63.30% · Sep 2026Low 61.90% · Jun 2026
60%61.3%62.5%63.8%65%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 62.00%Mar 2026: 62.00%Jun 2026: 61.90%Sep 2026: 63.30%61.90%63.30%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters63.30%61.90%62.00%62.00%
Public36.70%38.10%38.00%38.00%

Charges & Borrowings of Windlas Biotech

Open charges
₹73.3 Cr
Satisfied charges
₹183.4 Cr
Breakdown by lending institutions
The Hongkong and Shanghai Banking Corporation Limited₹40.00 Cr
Hdfc Bank Limited₹23.30 Cr
Others₹10.00 Cr
Latest charge details
DateLenderAmountStatus
27 May 2022The Hongkong and Shanghai Banking Corporation Limited₹40 CrOpen
04 Feb 2015Others₹10 CrOpen
28 Apr 2010Hdfc Bank Limited₹23.3 CrOpen
16 Apr 2021Others₹20 CrSatisfied
16 Mar 2021Others₹20 CrSatisfied

Total charge records: 29 View all charges

Employees and EPFO Compliance at Windlas Biotech

Windlas Biotech Limited has a workforce of 1,153 employees as of Feb 18, 2026.

Employee count
1,153
Active EPFO establishments
1
Employee growth
8.57%
Premium access

Employee and EPFO history for Windlas Biotech Limited

Monthly headcount, contribution history and filing status are in the company report.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Windlas Biotech

Premium access

GST registrations and filing compliance for Windlas Biotech Limited

State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Windlas Biotech

Premium access

Credit ratings, litigation, and regulatory alerts for Windlas Biotech Limited

Credit ratings, court records and regulatory alerts are in the company report.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Windlas Biotech

Premium access

MSME payment history for Windlas Biotech Limited

Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Windlas Biotech

Premium access

Corporate group structure for Windlas Biotech Limited

Parent, subsidiary, associate and joint venture records with holdings are in the company report.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Windlas Biotech

Premium access

MCA filings and documents for Windlas Biotech Limited

Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Windlas Biotech

Directors
05 May 2026
Tarashree Singhal was appointed as a Additional Director on 05 May 2026 & has been associated with this company since 5 months.
Activity
28 Jul 2025
Windlas Biotech Limited last Annual general meeting of members was held on 28 Jul 2025 as per latest MCA records.
Activity
31 Mar 2025
Windlas Biotech Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Uttarakhand.
Charges
20 Mar 2025
A charge registered on 13 Jul 2020 via Charge ID 100360093 with Sidbi was fully satisfied on 20 Mar 2025.
Charges
17 Mar 2025
A charge with The Hongkong And Shanghai Banking Corporation Limited of Rs. 40.00 Cr registered on 27 May 2022 with Charge ID 100575416 was modified on 17 Mar 2025.
Charges
08 Jan 2025
A charge with Hdfc Bank Limited of Rs. 23.30 Cr registered on 28 Apr 2010 with Charge ID 10223457 was modified on 08 Jan 2025.

Recent News on Windlas Biotech

Frequently Asked Questions about Windlas Biotech Limited

Windlas Biotech is an active public limited company in the pharma sector based in Dehradun, Uttarakhand, India. It was incorporated on 19 February 2001 (25+ years old) and is registered under CIN L74899UR2001PLC033407. Listed on BSE: 543329 and NSE: WINDLAS. The company has 1,153 employees.

Windlas Biotech reported revenue of ₹904.09 Cr for FY 2025-26 (up 18.98% YoY) based on consolidated financials.

The current directors of Windlas Biotech are:

The primary industry of Windlas Biotech is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.

Yes. Windlas Biotech is listed on both BSE (code: 543329) and NSE (symbol: WINDLAS).

Windlas Biotech can be reached at the registered office: 401 Mohabewala Industrial Area, Dehradun, Uttarakhand, India – 248110, or through the website windlas.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - compiled from official filings and updated regularly.

Subscription plans available